Pentoxifylline Effects on Late-Onset Sepsis in Preterm Neonates: A Pilot Randomized Clinical Trial

Background: Despite the progress in the management of late-onset sepsis (LOS), it is the leading cause of mortality in preterm infants worldwide. Pentoxifylline is a methylxanthine with well-documented immunomodulatory properties, which may be an important approach to treating LOS.This study aimed to evaluate the efficacy and safety of adding oral pentoxifylline standard care among preterm neonates with LOS. Methods: In this trial, 47 preterm neonates with a confirmed diagnosis of LOS were allocated to either receive Pentoxifylline 10 mg/kg three times a day orally plus standard care (n=23) or the standard care alone for 6 days (n=24) using the block randomization method. The primary outcomes were the duration of C-reactive protein (CRP) negativity, duration of supplemental oxygen therapy, hospitalization and mortality rate. Secondary outcomes included the assessment of any adverse events that may have occurred during the study. Continuous data were analyzed using the independent t-test or Mann–Whitney U test. Chi-square and/or Fisher’s exact tests are used for categorical variables. The logistic regression analysis was also used for comparing mortality after adjusting for covariates. Results: The demographic characteristics, mothers/infants-related risk factors, use of antenatal steroids, neonatal resuscitation, antibiotic regimen, and surfactant administration were statistically similar between the intervention and control groups; however, respiratory support significantly differed. After adjusting for respiratory support, there was no significant difference regarding the duration of hospitalization (P=0.56), CRP negativity (P=0.69), supplemental oxygen therapy (P=0.94), and mortality rate (P=0.5) between the study groups. Conclusion: Adding oral pentoxifylline to standard care had no significant benefits on clinical and paraclinical outcomes in preterm neonates with LOS. Further clinical trials are needed to test the study hypothesis.

Authors

Institutions

Publication Details

Journal
Pharmaceutical Sciences
Published
2026-01-05
DOI
https://doi.org/10.34172/ps.026.42133
Primary Topic
Neonatal and Maternal Infections
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pentoxifylline Effects on Late-Onset Sepsis in Preterm Neonates: A Pilot Randomized Clinical Trial

Elnaz Shaseb, Sajad Khiali, Hila Asham, Mohammadbagher Hosseini et al.
Pharmaceutical Sciences
Neonatal and Maternal Infections
article

Pentoxifylline Effects on Late-Onset Sepsis in Preterm Neonates: A Pilot Randomized Clinical Trial

Elnaz Shaseb, Sajad Khiali, Hila Asham, Mohammadbagher Hosseini, Parvin Sarbakhsh, Donya Behzadi Mohammadi, Manizheh Mostafa Gharehbaghi
article en

Abstract

Background: Despite the progress in the management of late-onset sepsis (LOS), it is the leading cause of mortality in preterm infants worldwide. Pentoxifylline is a methylxanthine with well-documented immunomodulatory properties, which may be an important approach to treating LOS.This study aimed to evaluate the efficacy and safety of adding oral pentoxifylline standard care among preterm neonates with LOS. Methods: In this trial, 47 preterm neonates with a confirmed diagnosis of LOS were allocated to either receive Pentoxifylline 10 mg/kg three times a day orally plus standard care (n=23) or the standard care alone for 6 days (n=24) using the block randomization method. The primary outcomes were the duration of C-reactive protein (CRP) negativity, duration of supplemental oxygen therapy, hospitalization and mortality rate. Secondary outcomes included the assessment of any adverse events that may have occurred during the study. Continuous data were analyzed using the independent t-test or Mann–Whitney U test. Chi-square and/or Fisher’s exact tests are used for categorical variables. The logistic regression analysis was also used for comparing mortality after adjusting for covariates. Results: The demographic characteristics, mothers/infants-related risk factors, use of antenatal steroids, neonatal resuscitation, antibiotic regimen, and surfactant administration were statistically similar between the intervention and control groups; however, respiratory support significantly differed. After adjusting for respiratory support, there was no significant difference regarding the duration of hospitalization (P=0.56), CRP negativity (P=0.69), supplemental oxygen therapy (P=0.94), and mortality rate (P=0.5) between the study groups. Conclusion: Adding oral pentoxifylline to standard care had no significant benefits on clinical and paraclinical outcomes in preterm neonates with LOS. Further clinical trials are needed to test the study hypothesis.

Pharmaceutical SciencesVol. 32(1)
Tabriz University of Medical Sciences (IR)
Tabriz University of Medical Sciences, University of Tabriz
Good health and well-being
Openalex Percentile: Top 72%
Neonatal and Maternal Infections
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.